Myra Vision Inc., a Shifamed portfolio company, announced it has closed on $25 million in Series B financing to support a first-in-human investigation of its novel glaucoma treatment.
Let’s start with Shifamed.
Shifamed is a medical technology innovation hub launched in 2007 and located in Silicon Valley.
The company is focused on resolving unmet clinical needs within the medical device industry via a portfolio of companies that include, in addition to Myra Vision:
- Adona Medica
- Akura Medical
- Atia Vision
- Supira Medical
- Tioga Cardiovascular
Now Myra Vision.
Myra Vision is developing a novel technology that enables safe outflow control for maximum reduction of intraocular pressure (IOP) while simultaneously reducing complexity and complication rates.
And the financing?
The company’s funding round was led by Cormorant Asset Management, a Boston-based investment management company, and included The Capital Partnership (TCP) and PA MedTech VC Fund, as well as Shifamed angel investors.
So what’s this novel technology?
Myra Vision’s Calibreye System is a novel treatment designed to potentially enhance IOP reduction in patients with moderate to severe glaucoma.
According to President and CEO Robert Chang, the system aims to enable “physicians to safely optimize aqueous flow and effectively manage the evolving clinical needs of each patient.”
Any clinical data on it yet?
In progress!
According to Clinical Trials.gov, a prospective, nonrandomized, open-label feasibility clinical trial (NCT05885022) is currently enrolling an estimated 30 patients (ages 18+) with open-angle glaucoma in order to assess the safety and feasibility of the Calibreye System over a 12-month period.
Patient criteria?
Participants must have an IOP of ≥ 18mmHg and ≤ 45mmHg at the baseline visit and a visual field mean deviation score of -3dB or worse.
See here for the full inclusion and exclusion criteria.
What’s being measured?
Primary outcome measures are listed as the following:
- Percentage change in IOP from baseline to 12-month visit
- Occurrence of adverse events (number and percentage)
The secondary outcome measure is the change in the number of glaucoma medications used compared to baseline.
When can we expect data?
According to Clinical Trials.gov, the study was initiated on May 31, 2023 with an estimated completion by April 2025.
Stay tuned for updates in the meantime!